Cleveland BioLabs (CBLI), Panacela Labs Receive $4.6M Contract in Russia for Xenomycins Development

November 27, 2012 7:07 AM EST Send to a Friend
Cleveland BioLabs, Inc. (Nasdaq: CBLI) and Panacela Labs, Inc. announced award of a contract valued at 146 million rubles, or approximately $4.6 million (based on current exchange rates), with the Ministry of Industry and Trade of the Russian Federation for development of Xenomycins, a family of compounds in development as anti-infective agents. The contract, issued under the Russian Federation's "Pharma 2020" development initiative, provides matching funding over a period of approximately three years, which will be used to support preclinical and clinical studies.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Corporate News, FDA

Add Your Comment